CurrentCareSourcePolicy N/A

UTILIZATION MANAGEMENT MEDICAL POLICY

Policy assesses medical necessity and recommends whether to approve coverage of Viltepso (viltolarsen) for treatment of Duchenne muscular dystrophy (DMD) in patients with DMD gene mutations amenable to exon 53 skipping. It summarizes clinical evidence, guideline context, and issues a non-recommendation for approval based on current evidence.

Policy Summary

PayerCareSource

PolicyUTILIZATION MANAGEMENT MEDICAL POLICY

Policy CodePolicy N/A

Change TypeAnnual Revision - No criteria changes

Effective Date

Next Review Date

Key ActionGenetic testing for a DMD mutation in a blood sample is always required to characterize mutation and determine eligibility; providers should note the policy provides no recommended authorization criteria and recommends not to approve Viltepso.

SourceLink

POLICY UPDATE CHANGES

Annual Revision summary states 'No criteria changes' for the 08/21/2024 review.

1Primary product assessed

0Recommended Indications for Approval

1DMD exon target discussed (exon 53)

Oct 2025Confirmatory trial primary completion

Coverage Summary

Policy assesses Viltepso (viltolarsen) for treatment of Duchenne muscular dystrophy (DMD) in patients with DMD gene mutations amenable to exon 53 skipping. The FDA granted Viltepso accelerated approval based on increases in dystrophin production, and a confirmatory Phase III trial (RACER53, NCT04768062) is ongoing with an estimated primary completion in October 2025. Based on limited clinical efficacy data — small increases in dystrophin and uncertain correlation with meaningful clinical outcomes — the policy recommends not to approve Viltepso for DMD at this time.

Key stats & evidence snapshot

Primary product assessedViltepso (viltolarsen)

Recommended Indications for ApprovalNone (policy: approval not recommended)

DMD exon target discussedExon 53

Estimated primary completion date (RACER53)Oct 2025

Pivotal dystrophin changeIncrease from 0.6% to 5.9% of normal dystrophin at Week 24/25

Pivotal study sample size (treated at approved dose)n = 8 treated with approved dose; pivotal cohort n = 16 with extension n = 16

Confirmatory trial (RACER53) detailsRACER53 (NCT04768062), ambulatory n = 74, estimated primary completion Oct 2025

Not Recommended / Criteria

Conditions Not Recommended for Approval

Coverage of Viltepso is not recommended in the following situations:

ALL of the following

Duchenne Muscular Dystrophy (DMD)
Approval is not recommended due to unclear benefit and lack of clinical efficacy data for Viltepso in DMD amenable to exon 53 skipping.
ALL of the following
- Pivotal study demonstrated measurable increase in dystrophin but significance of small change not correlated with clinical benefit.
- Pivotal data did not provide information on cardiac and respiratory outcomes.
- Pivotal data lacked robust functional outcomes related to motor function.
- Approval was granted via accelerated pathway and may be contingent on confirmatory trial results.
- Systematic review and meta-analysis of exon skipping therapies (including Exondys 51, drisapersen) do not show benefit.
Coverage is not recommended for any circumstance not listed in Recommended Authorization Criteria
There are no Recommended Authorization Criteria provided in this policy (section states 'None').

ref": "b1_0"

title": "Conditions Not Recommended for Approval"

Provider Actions / Requirements

Documentation Required

Genetic testing requirement (informational)

Genetic testing for a DMD mutation in a blood sample is always required to fully characterize the mutation and determine eligibility for mutation-specific therapies or trials. If no mutation is identified but the patient has signs or symptoms of DMD, a muscle biopsy may be clinically indicated.

Prior Authorization

No recommended authorization criteria provided

The policy states: "RECOMMENDED AUTHORIZATION CRITERIA None." Providers should note that the payer's policy does not provide approval criteria and the policy recommends not to approve Viltepso.

Denial Risk

Coverage denied/recommended against

Coverage of Viltepso is not recommended for DMD patients amenable to exon 53 skipping due to unclear benefit and lack of clinical efficacy data; as a result, claims may be denied consistent with this policy.

Background & Evidence Summary

Viltepso (viltolarsen) is an antisense oligonucleotide designed to bind exon 53 of dystrophin pre-mRNA and induce exclusion of exon 53 during mRNA processing, restoring the reading frame for mutations amenable to exon 53 skipping and producing a shortened, partially functional dystrophin protein. The FDA granted accelerated approval for this indication based on increased dystrophin observed in a limited number of treated patients, but clinical efficacy data are limited (pivotal data derived from small cohorts with modest dystrophin increases and incomplete functional and cardiac/respiratory outcome data). A confirmatory Phase III trial, RACER53 (NCT04768062), is ongoing to verify clinical benefit, with an estimated primary completion date of October 2025.

Evidence items (pivotal & confirmatory)

Pivotal dystrophin change0.6% baseline to 5.9% of normal dystrophin at Week 24/25

Pivotal study sample sizePrimary pivotal report: n = 16 (with n = 8 treated at approved dose cited in prescribing info); extension included 16

Confirmatory trial (RACER53)NCT04768062, planned n = 74 ambulatory patients; estimated primary completion Oct 2025

Amenable to exon 53 skipping: patients with a confirmed DMD gene mutation whose reading frame can be restored by skipping exon 53, making them potential candidates for viltolarsen therapy.